特稿｜处于“十字路口”的英国制药业

Core Viewpoint - The UK pharmaceutical industry is at a critical juncture, facing the challenge of either leading a new wave of industrial transformation or becoming marginalized in the face of intense competition driven by advancements in artificial intelligence, genetic technology, and synthetic biology [1] Group 1: Strengths - The UK pharmaceutical industry benefits from a strong scientific foundation and a well-developed data ecosystem, with the UK Biobank being a valuable asset containing detailed genetic and health data from 500,000 volunteers, making it a global hub for drug target discovery [1] - The close collaboration between universities and pharmaceutical companies in the UK, exemplified by the Cambridge Biomedical Campus, reduces friction costs in technology transfer, facilitating innovation [2] - The UK Medicines and Healthcare products Regulatory Agency has been praised for its agility, having doubled the speed of clinical trial approvals through digital transformation, allowing some low-risk studies to be approved within 14 days [2] Group 2: Challenges - The integration of emerging technologies is reshaping the global biopharmaceutical industry, but the UK faces challenges in adapting to these changes, particularly in converting vast amounts of genetic data into viable drug targets [3] - Internal pressures, such as regulatory adjustments post-Brexit and structural issues within the National Health Service, hinder innovation in the UK pharmaceutical sector [3] - The UK pharmaceutical industry is described as having strong scientific capabilities but weak commercialization, with major companies like Merck announcing the closure of labs in London due to a lack of progress in life sciences investment [4] Group 3: Market Constraints - Many UK startups are being acquired by American companies due to a lack of risk-taking investors in the UK, leading to funding challenges during critical growth phases [4] - The National Health Service's policies limit the market entry of innovative drugs, with low reimbursement prices and slow approval processes affecting the efficiency and commercial returns of new drug launches [4] - Post-Brexit, increased non-tariff barriers have slowed supply chain responsiveness, and restrictions on the free movement of European scientists have made it harder for UK labs to recruit top talent [5]